Companies › Foghorn Therapeutics
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FHD-286 | – | Phase 1 | Advanced Hematologic Malignancy; Small Cell Lung Cancer; Acute Myeloid Leukemia | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04891757 | FHD-286 | Phase 1 | Advanced Hematologic Malignancy | Oncology | Jun 2027 |
| NCT07551635 | FHD-286 | Phase 2 | Small Cell Lung Cancer | Oncology | Jan 2028 |
| NCT07283094 | FHD-286 | Phase 1 | Acute Myeloid Leukemia | Oncology | May 2028 |
Cash of $80m on 2026-09-30; operating cash outflow about $82m a year; runway about 12 months at that burn, to Sep 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.